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 i g  h  l  i  g  h  t  s
Mesenchymal  stem  cells  (MSCs)  were  isolated  from  rats  that received  doxorubicin.
Doxorubicin  had  toxic  effects  on MSCs.
MSCs  grew  up  in  lower  rates  and  had decreased  alkaline  phosphatase  production.
MSCs  failed  to  express  connexin  43 and  troponin  T.
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a  b  s  t  r  a  c  t
Doxorubicin  (dox)  is an effective  chemotherapeutic  agent  that  leads  to  cardiotoxicity.  An  alternative  treat-
ment for  dox-cardiotoxicity  is  autologous  mesenchymal  stem  cells  (MSCs)  transplantation.  It remains
unclear  if  dox  has  deleterious  effects  on  MSCs  from  subjects  under  chemotherapy,  therefore  this  study
aimed  to evaluate  dox  in  vivo toxicological  effects  on ex vivo  cultured  MSCs,  inferring  whether  autolo-
gous  transplantation  may  be  an  alternative  treatment  in  patients  who  are  exposed  to  the  drug.  Wistar  rats
received  either  dox or saline.  Following  treatments,  animals  were  sacriﬁced  and  bone  marrow  MSCs  were
isolated,  characterized  for cell  surface  markers  and  assessed  according  to their  viability,  alkaline  phos-
phatase  production,  and  proliferation  kinetics.  Moreover,  MSCs  were  primed  to cardiac  differentiationesenchymal stem cells
ell therapy
ardiac differentiation
and  troponin  T and  connexin  43  expressions  were evaluated.  Compared  to control,  undifferentiated  MSCs
from dox  group  kept  the pattern  for surface  marker  and had similar  viability  results.  In  contrast,  they
showed  lower  alkaline  phosphatase  production,  proliferation  rate, and  connexin  43 expression.  Primed
MSCs from  dox  group  showed  lower  troponin  T levels.  It  was  demonstrated  a  toxic effect of  dox  in  host
MSCs.  This  result  renders  the  possibility  of  autologous  MSCs  transplantation  to treat  dox-cardiotoxicity,
tablewhich  could  be a non-sui
. Introduction
One of the most effective chemotherapeutic agents used for
reatment of hematological and solid tumors is doxorubicin (dox)
Butany et al., 2009) However, it causes a dose-dependent car-
iotoxicity that may  lead to irreversible heart failure by different
Abbreviations: AP, alkaline phosphatase; BCIP, 5-bromo-4-chloro-3-indolyl
hosphate; BSA, bovine serum albumin; DMEM,  Dulbecco’s modiﬁed Eagle’s
edium; dox, doxorubicin; FBS, fetal bovine serum; MSCs, mesenchymal stem
ells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NBT,
itroblue tetrazolium salt; PBS, phosphate buffered saline; PVDF, polyvinylidene
iﬂuoride; SDS, sodium dodecyl sulfate; TBS, tris buffered saline; TBST, tris buffered
aline with Tween.
∗ Corresponding author. Tel.: +55 31 3409 2274; fax: +55 31 3409 2230.
E-mail address: maira oliveira@yahoo.com (M.S. Oliveira).
378-4274/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.toxlet.2013.11.023 option  for  subjects  receiving  such  antineoplastic  agent.
© 2013 Elsevier Ireland Ltd. All rights reserved.
pathogenic mechanisms which have not been completely eluci-
dated (Gianni et al., 2008). Production of reactive oxygen species,
calcium imbalance and apoptosis are considered among the patho-
logical mechanisms for dox-induced cardiotoxicity (Gianni et al.,
2008; Tan et al., 2010; Zhang et al., 2011).
A progressive reduction of left ventricular function, detected by
different echocardiography approaches, either in animal models
(Oliveira et al., 2013), or in a signiﬁcant proportion of pediatric
(Lipshultz et al., 2012), adult (Tassan-Mangina et al., 2006) and
elderly (Aapro et al., 2011) patients, is observed during the course
of the anti-cancer therapy, leading to a life-threatening conges-
tive heart failure. While cardiotoxicity can develop at no speciﬁc
time once the treatment has begun, identifying cardioprotective
strategies to minimize the long-term damage caused by anthracy-
clines is imperative. In this context, many alternatives have been
investigated either in experimental models or in clinical trials in
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rder to prevent or diminish cardiac dysfunction, such as dexra-
oxane (Lipshultz et al., 2010), carvedilol (Machado et al., 2008),
lant extracts (Du and Lou, 2008) and stem cell therapy (Chen et al.,
010). Nevertheless, none of those are really established in rou-
ine medical practice to date. Between 1966 and 2010, Van-Dalen
t al. (2011) investigated randomized controlled trials in which
ny cardioprotective agent was compared to no additional ther-
py or placebo in cancer patients (children and adults) receiving
nthracyclines. Although dexrazoxane had showed the potential
o prevent heart damage, the authors found no deﬁnitive conclu-
ions about a real cardioprotective agent. A promising alternative
or prevention or treatment of tissues and organs is the regenera-
ive medicine using stem cells. Autologous mesenchymal stem cell
MSCs) transplantation is an obvious ﬁrst option when thinking of
 routine practice, given the ease of cell isolation and in vitro expan-
ion required for therapy (Mayhall et al., 2004; Wang et al., 2012).
owever, the autologous MSCs transplantation for cardiac repair in
atients under chemotherapy must be re-thought. It is paramount
o ﬁrstly understand the effects of dox in such cell population before
onsidering its use. For this reason, the aim of the present research
as to study whether MSCs niches are affected by dox treatment
n subjects under chemotherapy.
. Materials and methods
.1. Dox cytotoxicity testing
Neonatal ventricular cardiomyocytes, adipose tissue derived
SCs and breast cancer MDA-MB 231 (ATCC® HTB-26TM) cell cul-
ures were evaluated for dox cytotoxicity. Cardiomyocytes (Ott
t al., 2008) and MSCs (Oliveira et al., 2013) were obtained as
reviously described. The cell cultures were seeded on 24-well
lates at 5 × 104 cells/cm2. Thereafter, they were incubated in a
umidiﬁed atmosphere with 5% CO2 at 37 ◦C using Dulbecco’s
odiﬁed Eagle’s medium (DMEM) high glucose (Sigma–Aldrich)
upplemented with 10% fetal bovine serum (FBS) (Cripion Biotec-
ologia LTDA), 5 mM sodium bicarbonate (Cinética Química Ltda),
enicillin (100 U/mL), streptomycin (0.1 mg/mL), amphotericin B
0.25 mg/mL) (Sigma–Aldrich), and gentamicin (60 mg/L; Schering-
lough). After 24 h, media was changed and was  added 5 mol/l
f dox [dox hydrochloride (Adriblastine®, Pﬁzer)] on the plates.
ox concentration was used as previously described (Spallarossa
t al., 2004). The length of incubation was determined by evaluating
he time where 50% of cardiomyocytes died. Then, this incubation
ime was performed for all cell cultures. Afterward, to determine
he cytotoxic effect of dox on the different cell types, cell viabil-
ty was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
etrazolium bromide (MTT) assay (Cat. M-6494; Invitrogen) as pre-
iously described by Paula et al. (2013). Brieﬂy, 24 h after plating the
ells, medium was changed to 170 l of the MTT  solution (5 mg/ml)
nd 210 l of basal media (DMEM/10% FBS). Cells were, then,
ncubated in a humid 5% CO2 atmosphere at 37 ◦C. 2-h later, the
recipitated formazan crystals were solubilized by adding 210 l
f sodium dodecyl sulfate (SDS)-10% HCl. After 18 h, 100 l of solu-
ion was transferred to a 96-well plate, and the optical density was
easured at 595 nm using a microplate reader. Data is from three
ndependent experiments.
.2. Animals and experimental groups
Sixteen male 6–8 weeks old Wistar rats weighing 300–350 g
ere studied. Animals were kept in climate-controlled environ-
ent under a 12-h light/dark cycle with free access to standard
odent chow and water. All experimental protocols were performed
n accordance with the guidelines of the Institutional Animal Caretters 224 (2014) 380– 386 381
and Use Committee in place at the University (protocol number
176/2010).
Animals were allocated into two groups containing eight rats
each: control group [saline intraperitoneal injection (i.p.)] and dox-
treated group [dox hydrochloride (Adriblastine®, Pﬁzer) 5 mg/kg;
i.p.]. Animals were weighted weekly and the dox dosage was prop-
erly calculated to each animal. The injections were given once a
week for four weeks. After 48 h of the last dox/saline adminis-
tration, animals were anaesthetized and sacriﬁced by overdose of
isoﬂurane anesthesia. The cumulative dose of dox used was  previ-
ously demonstrated to be effective and to promote cardiotoxicity
and heart failure (Oliveira et al., 2013). In order to conﬁrm the
occurrence of cardiac dysfunction, animals from both groups were
evaluated by echocardiography examination before (baseline) and
after dox treatment.
2.3. Bone marrow derived MSCs isolation and culture
Following the euthanasia, bone marrow MSCs were isolated
from rats of both control and dox groups, as previously described
(Assis et al., 2010) with minor modiﬁcations. Brieﬂy, bone mar-
row was  ﬂushed out from tibias and femurs of both control and
dox-treated rats, using DMEM high glucose supplemented with
sodium bicarbonate, penicillin, streptomycin, amphotericin B, and
gentamicin. This content was centrifuged, and the pellet contain-
ing MSCs was  put into suspension in the aforementioned medium
added with 10% FBS and, then, plated in 75 cm2 ﬂasks. Cell cul-
tures were kept in a humidiﬁed atmosphere with 5% CO2 at 37 ◦C
for 24 h before the ﬁrst medium change. The medium was  then
changed every 2–3 days. Cell adherence to cell culture ﬂask guar-
anteed mesenchymal cell population enrichment. The cells were
allowed to grow near conﬂuence, and were split in a 1:3 ratio using
0.25% trypsin–EDTA. Fourth passage bone marrow derived MSCs
were used in all experiments.
2.4. Cellular characterization by indirect immunoﬂuorescence
Cells were ﬁxed in 4% paraformaldehyde for 10 min  at room
temperature, permeabilized in 0.1% Triton X-100 (Sigma) for 1 h at
room temperature. Samples were blocked with 1% bovine serum
albumin (BSA) and 5% goat serum in phosphate buffered saline
(PBS) solution and incubated for 1 h at room temperature fol-
lowed by two washes with PBS. Primary antibodies [CD45 (cat.#
610266), CD54 (cat.# 554967), CD73 (cat.# 551123) and CD90
(cat.# 554895), all from BD Biosciences, USA] were added in 1%
BSA in PBS solution and incubated overnight at 4 ◦C at 1:100 dilu-
tion. Samples were washed with PBS twice. Secondary antibodies
[Alexa Fluor dye conjugated (Invitrogen, USA)] were diluted (1:500)
in the same solution as the primary antibodies and incubated at
room temperature for 1 h in dark. Samples were washed with PBS
twice. Coverslips were sealed with hydramount aqueous media
(Cat. HS-106; National diagnostics) and analyzed with a Zeiss LSM
510—Meta confocal microscope. Nine random ﬁelds were collected
from each experimental group. Data is from three independent
experiments.
2.5. Cell viability assay
Cell viability was assessed by the MTT  assay as aforementioned.
In these studies, cultures of 5 × 104 cells/cm2 were seeded on 24-
well plates. Data is from three independent experiments.2.6. Alkaline phosphatase (AP) activity
AP activity was  evaluated with the 5-bromo-4-chloro-3-indolyl
phosphate (BCIP)/nitroblue tetrazolium salt (NBT) Kit assay as
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(p = 0.0001). Considering that both groups had either same cell
seeding counts or MTT  results, the data of NBT–BCIP test indicates
that MSCs from dox group had AP production deﬁciency (Fig. 3).
Table 1
Echocardiography variables obtained from Wistar rats following four weeks of either
doxorubicin or saline treatments, showing an effective induction of cardiac failure
on  animals exposed to the drug.
Echocardiography variables Groups p-Value
Control Doxorubicin
Heart rate (bpm) 332 (9.9) 332 (49.9) 0.906782 M.S. Oliveira et al. / Toxicol
escribed by the manufacturer (Cat. 00-2209; Invitrogen). Brieﬂy,
ultures of 5 × 104 cells/cm2 were seeded in 24-well plates and,
4 h later, 200 l of the BCIP–NBT solution was added. After a 2-h
ncubation period, the insoluble purple precipitate was  solubilized
y adding 210 l of SDS-10% HCl. After 18 h, 100 l of solution
ere transferred to a 96-well plate, and the optical density was
easured at 595 nm using a microplate reader. Data is from three
ndependent experiments.
.7. Cell proliferation study
Cell proliferation was assessed by plating 1 × 103 cells/cm2 in
-well plates (day 0). For each one of the four time points, cells
ere seeded in three independent wells. Following cell attachment,
ells from both control and dox groups were harvested on days 1,
, 5, 7 and counted in triplicates using a hemocytometer. Lastly,
rowth curves were determined. Three independent experiments
ere considered.
.8. Cardiomyogenic differentiation induction
Plasticity of MSCs toward cardiomyogenic phenotype was
ssessed after inducing the cells to differentiate into cardiomy-
cytes using a standard induction medium (Planat-Bénard et al.,
004). This medium basically consisted of: DMEM/20% FBS
dded with IL-3, IL-6, SCF, 10−4 M of 2-mercaptoetanol, 2 mM
f l-glutamine, 200 g/ml human apo-transferrin, and 10 g/ml
ecombinant human insulin. Cells were cultured on 25 cm2 ﬂasks.
hen cells reached approximately 80% conﬂuence, they were cul-
ured with the induction media (4 ml/ﬂask changing every two
ays). MSCs from both dox and control groups were kept in basal
edium, which consisted of DMEM supplemented with 10% FBS as
ontrol.
.9. Western blotting
Brieﬂy, bone marrow derived MSCs from dox and control groups
ere washed twice with ice-cold PBS, harvested by scraping and
ysed in a lysis buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris–HCL
H 8.0, 0.5% Nonidet P-40). After incubation on ice, the cells of each
ample were homogenized by vortex and sonicated. The respec-
ive homogenates were centrifuged at 16,100 × g for 20 min  at
◦C. Protease inhibitors (Sigma, USA) were added to each sam-
le. The protein amount was assessed by the Bradford assay. Thirty
icrograms of protein of each group were subjected to SDS-PAGE
lectrophoresis and, then, transferred to a polyvinylidene diﬂuo-
ide (PVDF) membrane (n = 3 in each group). The membrane was
locked with 5% skim milk in Tris buffered saline (TBS) with
ween (TBST; TBS plus 0.1% Tween 20) for 60 min  and then incu-
ated with primary antibody. Commercially available antibodies
or connexin-43 (cat.# 11370), cardiac troponin-T (cat.# 8295), and
lpha-actinin (cat.# 9465) (all from Abcam, UK) and GAPDH (cat.#
5778, from Santa Cruz Biotechnology, USA) were used at 1:8000,
:1000, 1:1000, and 1:250 dilutions, respectively. GAPDH was used
s an input control. Incubations were carried out overnight. After
hree washes with TBST, the membranes were incubated with
eroxidase-conjugated secondary antibody (1:5000) (Sigma, USA)
or 1 h at room temperature. Blots were visualized by enhanced
hemiluminescence and quantitatively analyzed using Image J soft-
are. Three independent experiments were done.
.10. Statistical analysisAll experiments were repeated three times in triplicate, and the
ata were presented as mean (standard deviation). The variables
ere submitted to both normality and homoscedasticity analyses.tters 224 (2014) 380– 386
For datasets with normal distribution, statistical signiﬁcance was
determined by Student’s t-test for two  groups or one-way analysis
of variance (ANOVA) for multiple groups with post hoc test using
Tukey method. Variables with non-normal distribution were ana-
lyzed with Mann–Whitney post test. Signiﬁcance was  considered
for 5% (p < 0.05). Analyses were done in R software program (2.11
version).
3. Results
3.1. Dox showed cytotoxic effect for breast cancer cells,
cardiomyocytes and MSCs
As expected for dox, which is a chemotherapy agent that
leads to cardiotoxicity, the cellular viability for breast cancer cells
and cardiomyocytes decreased after incubation with the drug.
MTT  metabolization for cancer cells was  69(12.26)% of its con-
trol and for cardiomyocytes was  65(9.54)% of its control. Moreover,
MTT  metabolization for MSCs incubated with dox also decreased,
corresponding to 83(12.74)% of control, indicating an in vitro dox-
cytotoxic effect on MSCs (Fig. 1).
3.2. In vivo exposure to dox promoted cardiotoxicity
Animals under dox treatment showed cardiac dysfunction. Both
control and dox groups had similar baseline echocardiography
parameters. At the end of the experiment, compared to control,
dox group presented signiﬁcant decreased values of ejection frac-
tion, fractional shortening, longitudinal strain, and radial strain,
indicating an effective induction of a cardiotoxicity model (Table 1).
3.3. MSCs from dox group kept the cell surface marker pattern
MSCs showed ﬁbroblast-like morphology and the cell culture
was enriched following the passages. Similar to control group, MSCs
isolated from rats that received dox treatment were positive for
CD54, CD73, CD90, and negative for CD45 expression, as expected
for undifferentiated MSCs according to the International Society for
Cellular Therapy (Dominici et al., 2006) (Fig. 2).
3.4. MSCs from dox group were viable but with reduction on AP
production
The values detected for MTT  metabolization were similar for
both groups (p = 0.0516). On the other hand, the values detected
for NBT–BCIP test were statistically different between the groupsEjection fraction (%) 68.9 (1.9) 54.4 (4.4) 0.0056
Fractional shortening (%) 36.9 (2.1) 28.8 (6.1) 0.0084
Longitudinal strain (%) 15.2 (4.2) 7.1 (2.0) 0.0036
Radial strain (%) 17.1 (6.1) 8.1 (1.1) 0.0148
M.S. Oliveira et al. / Toxicology Letters 224 (2014) 380– 386 383
Fig. 1. Doxorubicin (dox) cytotoxicity in breast cancer cells (MDA-MB 231), cardiomyocytes and mesenchymal stem cells. Cellular viability was  decreased in all cell cultures
after  10 h of incubation with 5 mol/l doxorubicin, compared to the respective control (N = 9, *p < 0.01, **p < 0.05).
Fig. 2. Immunophenotype characterization for bone marrow mesenchymal stem cells derived from either control (a, left side of the panel) or doxorubicin (b, right side of the
panel)  groups showed the expected pattern of expression, being positive for CD54, CD73, CD90 and negative for CD45. Cells incubated only with secondary antibody were
used  as a negative control. Scale = 10 m.  Data shown is from one of the three independent experiments that were done (N = 9).
Fig. 3. Cellular viability and alkaline phosphatase (AP) production for bone marrow mesenchymal stem cells derived from either control or doxorubicin (dox) groups. Cells
from  dox group showed decreased AP production compared to control (N = 9, *p < 0.01).
384 M.S. Oliveira et al. / Toxicology Le
Fig. 4. Doxorubicin (dox) inhibits mesenchymal stem cell proliferation. Mesenchy-
mal  stem cells derived from dox group show decreased counting values compared
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F
W
a
(o  control after day ﬁve of plating (N = 9, *p < 0.05).
.5. Dox induced lower cell proliferation rate of MSCs in culture
The cellular growth curve pointed out differences from control
nd dox groups (Fig. 4). MSCs from dox group had lower prolifer-
tion rates at day 5 and day 7 after seeding, compared to control
p < 0.05).
.6. Alterations on connexin-43 and cardiac troponin T
xpression were detected on cells from dox group
Undifferentiated cells from dox group had decreased connexin-
3 expression compared to control, when evaluated by western
lotting (p < 0.05). Priming MSCs to cardiomyogenic lineage was
upposed to induce cardiac troponin T expression. Indeed it was
etected for MSCs from control group. Otherwise, cells from dox
roup did not express cardiac troponin T following cardiomyogenic
ifferentiation induction (Fig. 5).
. Discussion
Dox remains among the most effective agents against
ematopoietic and solid tumors, and for that reason, it has been
rescribed worldwide, despite the possible occurrence of car-
iotoxicity (Aapro et al., 2011; Butany et al., 2009; Gianni et al.,
008; Lipshultz et al., 2012; Tassan-Mangina et al., 2006). Even
o, there is no consensus about a real effective treatment for dox-
nduced cardiotoxicity in clinical practice, to the date (Du and Lou,
008; Lipshultz et al., 2010; Machado et al., 2008; Van-Dalen et al.,
011).
ig. 5. The expression of both troponin T and connexin 43 proteins was decreased on me
estern blotting was used to study troponin T and connexin 43 expression after doxorub
 positive control, as seen on the left side of the panel (a). Quantiﬁcation of troponin T an
b  and c) (N = 3, *p < 0.05). Dox, doxorubicin; MSC, mesenchymal stem cell; pMSC, primedtters 224 (2014) 380– 386
Among the alternatives that have been investigated to prevent
or repair cardiac injuries, stem cell transplantation may  be con-
sidered as an option, due to promising data from experimental
studies involving several heart failure models. Various undiffer-
entiated stem cell sources have been proposed for regenerative
medicine, each having their advantages and drawbacks. Embryonic
stem cells are characterized by pluripotency and an unlimited self-
renewal capacity, but they may  present high tumorigenic potential
and their use is associated with major ethical concerns. In con-
trast, MSCs are not ethically restricted, but show limited capacity
to proliferate and differentiate into different cell lineages (mul-
tipotency) (Barreto Filho and Oliveira, 2012). Even though MSCs
do not terminate differentiation toward cardiomyogenic lineage,
these cells are employed in cardiac repair due to their paracrine
effects. MSCs have been shown to promote the preservation of
heart function in acute as well as chronic lesions, mainly myocar-
dial infarction (Carvalho et al., 2013; Mias et al., 2009) and chronic
ischemic heart failure (Lilyanna et al., 2013), and even in dox
induced cardiotoxicity models (Chen et al., 2010; Oliveira et al.,
2013).
Therefore, it is reasonable to hypothesize that the application of
those cells should preserve heart function following dox treatment
in clinical practice. Even though MSCs are not immunogenic and
may be used in allogenic transplants, the most obvious choice of
treatment is the use of autologous cells. In such scenario, it becomes
paramount to assess the quality and characteristics of MSCs from
the patient receiving dox. Here, we  ﬁrstly investigated whether
dox was toxic to MSCs in vitro. Then, we performed an in vivo
study designed to promote cardiac toxicity due to dox adminis-
tration, thus evaluating MSCs isolated from control and dox hosts
according to: adherence to plastic, cell morphology and phenotype,
viability, proliferation, alkaline phosphatase production and poten-
tial for differentiation toward cardiomyocyte cell fate. As we found
a cytotoxic effect of the drug to MSCs in vitro, it was reasonable
to think that the dox treatment could interfere in the biological
aspects of MSCs from subjects receiving chemotherapy. Another
reason to consider a possible side effect of dox toward MSCs is
the fact that the drug is also related to other organotoxic poten-
tials, raising the possibility for the occurrence of cytotoxic effects
on different organs and tissues. It was  demonstrated that dox pro-
moted pro-inﬂammatory and pro-ﬁbrotic stress responses in the
liver by increasing mRNA expression of tumor necrosis factor alpha
and connective tissue growth factor and leading to DNA damageto increased serum urea nitrogen and creatinine levels, meanwhile
kidney tissues studies demonstrated increases in the expression of
pro-apoptotic caspase-3, Bad and Bax proteins, reduction in the
senchymal stem cells isolated from animals that had been exposed to doxorubicin.
icin treatment. GAPDH was used as a loading control and heart tissue was used as
d connexin 43 expression were shown as values normalized by GAPDH expression
 mesenchymal stem cells.
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xpression of anti-apoptotic Bcl-2 and Bcl-xL genes and eleva-
ions in lipid peroxidation and genomic DNA fragmentation (Lahoti
t al., 2012). Moreover clinical trial investigations reported myolo-
uppression, alopecia, nausea and vomiting in patients who  have
eceived dox either alone or in combined preparations (Raﬁyath
t al., 2012).
With respect to cytotoxic potential of dox to MSCs, it is presum-
ble that other anti-cancer drugs may  show similar side effects.
uring cancer treatment, combined chemotherapy preparations
re used to improve the efﬁcacy in killing cancer cells. Among
hem, the use of dox plus cyclophosphamide followed by doce-
axel plus trastuzumab to treat breast cancer (Saracchini et al.,
013), or the iPAD protocol which comprises bortezomid, dox
nd intermediate-dose dexamethasone to treat refractory multi-
le myeloma (Takamatsu et al., 2013), or even the CHOP protocol
hich comprises cyclophosphamide, dox, vincristine and pred-
isone in the treatment of various cancer types including refractory
on-Hodgkin lymphomas (Yang et al., 2013). Considering the data
resented here for the use of one drug alone (dox), it is possible
o assume that such common practice of combined chemotherapy
reparations probably make the side effects on MSCs even more
ramatic.
There are many protocols for the induction of cardiotoxicity
sing dox (Chen et al., 2010; De Angelis et al., 2010; Hazari et al.,
009; Hou et al., 2009; Kumar et al., 2011; Oliveira et al., 2013).
oute of administration, dose and number of applications seems
o differ and even drug manufacturers generate different effects
n vivo. Before studying stem cell toxicity induced by dox, we estab-
ished an in vivo model of cardiopathy induced by the drug. As
hown in echocardiography analysis, we successfully generated a
odel in which cardiotoxicity by dox is observed.
Next, we isolated bone marrow MSCs and evaluated a possi-
le toxic effect of dox in this cell population. In the present study,
he adipose tissue was not considered as source of MSCs because
ll animals from dox group showed markedly weight loss and the
acroscopic appearance of the fat seemed to be degenerated, inca-
able of being used. Our results indicate that treatment with dox
id not affect bone marrow MSC’s ability to adhere to plastic, allow-
ng similar isolation protocol as in the control group. In addition,
solated MSCs from both groups presented similar morphology and
mmunophenotype. In the present work, the MSC  population from
oth groups had a CD54+/CD73+/CD90+/CD45− phenotype. Reports
ave shown that MSCs express many different surface markers.
lthough differences are found the phenotype presented here
atches some of the markers that have been reported by others,
uch as CD73+/CD90+/CD105+/CD11b−/CD19−/CD45−/HLA-DR−
Dominici et al., 2006), CD90+/CD71−/CD34− (Jiang et al., 2006),
D54+/CD73+/CD90+/CD45− (Assis et al., 2010). It is possible to sug-
est, therefore, that isolated MSCs were not altered regarding their
ature during dox treatment.
In contrast with the aforementioned results, dox treatment
nduced lower alkaline phosphatase activity, slower prolifera-
ion rates, decreased connexin-43 production and hindered MSCs
apacity to respond to cardiomyogenic differentiation stimuli. Data
bout stem cell transplantation to regenerate heart injuries are
romising. The most discussed mechanism involved in the cardiac
issue repair is related to the paracrine effect of the MSCs, as those
ells do not terminally differentiate into cardiomyogenic lineage
Carvalho et al., 2013; Chen et al., 2010; Dai et al., 2005; Garbade
t al., 2009; Oliveira et al., 2013).
Even though is not well established weather MSCs are capable
f terminally differentiating into the cardiomyogenic lineage, those
ells are employed in a vast number of studies regarding treat-
ent of heart function. Those data show promising results and the
ore discussed mechanism by which MSCs repair heart tissue is
heir paracrine effects, although it is unclear which componentstters 224 (2014) 380– 386 385
are really secreted by the MSCs in the host tissues. The production
of two  proteins was  investigated in the present study, connexin
43 and troponin T. It is known that cardiomyocytes highly express
connexin 43 and are rich in GAP junctions, which are extremely
important to the maintenance of the conductivity of the electric
impulses throughout the cardiomyocytes (Valiunas et al., 2000).
Troponin T is a regulatory protein that is involved in the heart mus-
cle contraction (Watkins et al., 1995). The results presented here
showed that MSCs, isolated from subjects that had been exposed
to dox, had decreased connexin 43 expression and troponin T after
cardiomyogenic differentiation. Regarding cell therapy it is rea-
sonable to consider that part of transplanted cells may  stay in
an undifferentiated status, while others may  prime to differenti-
ation following the host tissue cells. So, the cell transplantation
may  account with healthy cells which could be able to express
proteins and secret products in the niche where they will host,
independently if they will follow differentiation or not. Thereafter
a cell transplantation procedure using MSCs isolated from donors
that had been exposed to dox could be unsuccessful due to a sink-
ing expression of two major proteins, connexin 43 and troponin T,
needed for the cardiomyocytes to do their ordinary functions.
Therefore, in addition to the already described cardiotoxicity,
the results of the current study show for the ﬁrst time, a cytotoxic
effect of dox on bone marrow MSCs from subjects receiving such
drug. In addition to bone marrow, other stem cell niches might
be compromised by the use of such drug, as demonstrated by De
Angelis et al. (2010) studying cardiac progenitor cells.
In conclusion, the present data demonstrated that dox promotes
biological impairments on MSCs, raising the possibility of autolo-
gous stem cell transplantation to treat dox-induced cardiotoxicity
as an improper option for subjects under chemotherapy with such
antineoplastic drug. In order to have a better comprehension of the
biological impairment of dox on MSCs, further studies are needed,
such as an evaluation of in vivo transplantation of the isolated MSCs
(derived from both the groups) into rats with dox-induced heart
failure, addressing the main question of the present study.
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